Genome-Based Biomarkers for Adverse Drug Effects, Patient Enrichment and Prediction of Drug Response, and their Incorporation into Clinical Trial Design

• Evans WE , McLeodHL: Pharmacogenomics – drug disposition, drug targets, and side effects.N. Engl. J. Med.348(6), 538–549 (2003).
   PubMed Web of Science ®Google Scholar
• Goldstein DB , TateSK, SisodiyaSM: Pharmacogenomics goes genomic.Nature Rev. Genet.4, 937–947 (2003).
   PubMed Web of Science ®Google Scholar
• Arranz MJ , CollierD, KerwinRW: Pharmacogenetics for the individualization of psychiatric treatment.Am. J. Pharmacogenomics1(1), 3–10 (2001).
   PubMedGoogle Scholar
• Fornier M , RisioM, Van Poznak C, Seidman A: HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology16(10), 1340–1352 (2002).
   PubMed Web of Science ®Google Scholar
• Roberts R , SullivanP, JoyceP, KennedyMA: Rapid and comprehensive determination of cytochrome P450 CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction.Hum. Mutat.16(1), 77–85 (2000).
   PubMed Web of Science ®Google Scholar
• Wei X , McLeodHL, McMurroughJ, GonzalezFJ, Fernandez-SalgueroP: Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.J. Clin. Investigation98(3), 610–615 (1996).
   PubMed Web of Science ®Google Scholar
• Rossouw JE , AndersonGL, PrenticeRL et al.: Risks and benefits of estrogen plus Progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA288, 321–333 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson GL , LimacherM, AssafAR et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA291, 1701–1712 (2004).
   PubMed Web of Science ®Google Scholar
• Price DT , RidkerRM: Factor V Leiden mutation and the risk for thromboembolic disease: A clinical perspective.Annals Int. Med.127, 895–903 (1997).
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP , RosingJ, Bloemenkamp KWM et al.: Oral contraceptives and the risk of venous thrombosis. NEJM344(20), 1527–1535 (2001).
   PubMed Web of Science ®Google Scholar
• Bloemenkamp KW , RosendaalFR, HelmerhorstFM et al.: Enhancement by Factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet346, 1593–1596 (1995).
   PubMed Web of Science ®Google Scholar
• Cushman M , KullerLH, PrenticeR et al.: Estrogen plus progestin and risk of venous thrombosis. JAMA292(13), 1573–1580 (2004).
   PubMed Web of Science ®Google Scholar
• Venter JC , AdamsMD, MyersEW et al.: The sequence of the human genome. Science291, 1304–1351 (2001).
   PubMed Web of Science ®Google Scholar
• Lander ES , LintonL, BirrenB et al.: Initial sequencing and analysis of the human genome. Nature409, 860–921 (2001).
   PubMed Web of Science ®Google Scholar
• Goldstein DB , CavalleriGL: Understanding human diversity.Nature437, 1241–1242 (2005).
   PubMed Web of Science ®Google Scholar
• Hinds DA , StuveLL, NilsenGB et al.: Whole-genome patterns of common DNA variation in three human populations. Science307, 1072–1079 (2005).
   PubMed Web of Science ®Google Scholar
• Nielsen R , BustamanteC, ClarkAG et al.: A scan for positively selected genes in the genomes of humans and chimpanzees. PLos Biol.3(6), 1–10 (2005).
   Google Scholar
• Botstein D , RischN: Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease.Nature Genet.33, 228–237 (2003).
   PubMed Web of Science ®Google Scholar
• Begovich AB , CarltonVEH, HonigbertLA et al.: A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet.75, 330–337 (2004).
   PubMed Web of Science ®Google Scholar
• Shiffman D , EllisSG, RowlandCM et al.: Identification of four gene variants associated with myocardial infarction. Am. J. Hum. Genet.77, 596–605 (2005).
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA , NtzaniEE, TrikalinosTA, Contopoulos-IoannidisDG: Replication validity of genetic association studies.Nature Genet.29, 306–309 (2001).
   PubMed Web of Science ®Google Scholar
• Hirschhorn JN , LohmuellerK, ByrneE, HirschhornK: A comprehensive review of genetic association studies.Genet. Med.4(2), 45–61 (2002).
   PubMed Web of Science ®Google Scholar
• Klein RJ , ZeissC, ChewEY et al.: Complement factor H polymorphism in age-related macular degeneration. Science308, 385–389 (2005).
   PubMed Web of Science ®Google Scholar
• Bottini N , MusumeciL, AlonsoA et al.: A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nature Genet.36(4), 337–338 (2004).
   PubMed Web of Science ®Google Scholar
• Grant SFA , ThorleifssonG, ReynisdottirI et al.: Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nature Genet.38(3), 320–323 (2006).
   PubMed Web of Science ®Google Scholar
• Ranade K , KirchgessnerTG, IakoubovaOA et al.: Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke36, 2346–2350 (2005).
   PubMed Web of Science ®Google Scholar
• Helgadottir A , ManolescuA, ThorleifssonG et al.: The gene encoding 5-lipoxygene activating protein confers risk of myocardial infarction and stroke. Nature Genet.36(3), 233–239 (2004).
   PubMed Web of Science ®Google Scholar
• Hakonarson H , ThorvaldssonS, HelgadottirA et al.: Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA293(18), 2245–2256 (2005).
   PubMed Web of Science ®Google Scholar
• Gerdes LU , GerdesC, KervinenK et al.: The apolipoprotein ε4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarcation: A substudy of the Scandinavian simvastatin survival study. Circulation101, 1366–1371 (2000).
   PubMed Web of Science ®Google Scholar
• Sacks FM , PfefferMA, MoyeLA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med.335(14), 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• Topol EJ : Arthritis medicines and cardiovascular events – “House of coxibs.” JAMA293(3), 366–368 (2005).
   Google Scholar

Websites

• FDA draft guidance document for industry and FDA staff: Class II special controls guidance document: drug metabolizing enzyme genotyping system. www.fda.gov/cdrh/oivd/guidance/1551.html
   Google Scholar
• FDA approval of a pharmacogenetic test related to Irinotecan (Camptosar) toxicity www.fda.gov/medwatch/SAFETY/2005/Jun_PI/Camptosar_PI.pdf.
   Google Scholar
• FDA draft guidance document for industry and FDA staff: pharmacogenomic data submissions. www.fda.gov/cder/guidance/6400fnl.pdf
   Google Scholar
• FDA draft guidance document for industry and FDA staff: Pharmacogenomic and genetic tests for heritable markers. www.fda.gov/cdrh/oivd/guidance/1549.html
   Google Scholar
• R Temple: A roadmap for developing and validating genomic classifiers for treatment selection. DIA Genomic Biomarkers Conference, Oct 7, 2005. www.fda.gov/cder/genomics/presentations_20051006/051007_10_Temple.pdf
   Google Scholar
• Freidlin B, Simon R: Use of genomic biomarkers in a regulatory environment. www.fda.gov/cder/genomics/presentations_20051006/051007_15_Simon.pdf
   Google Scholar
• Perlegen Sciences licenses late-stage compound from mitsubishi pharma. www.perlegen.com
   Google Scholar